California clinical trials · registry checked August 31, 2026
A study is a question, not a treatment promise.
This desk names the drug, condition, phase, California city and exact federal record. It also tells you when a study is observational, invitation-only or not a treatment study at all.
Registry records checked August 31, 2026. Status can change between checks. Licensed-prescriber and California legal review are pending; no review badge is claimed.
Read this first
“Recruiting” describes the record. It does not say you qualify.
ClinicalTrials.gov is a registry, not a booking service and not FDA approval. A sponsor enters the record. A local site may be recruiting while another site in the same study is not. The study team—not this site—decides eligibility after screening.
A trial contact is never a crisis service. If you may act on suicidal thoughts, call or text 988, call 911, or go to the nearest emergency department.
The snapshot
40 California records, sorted by what they actually do.
The scope is deliberately narrower than every study that mentions ketamine: ordinary anesthesia and pain-control trials are excluded. 17 active records closed to enrollment, 3 status-unknown records, and 1 suspended record appear separately below.
Contact routes checked Oct 2, 2026
A contact is a door. It is not an opening.
We record whether the federal study record posts a phone or email field. We do not copy contact names, email addresses, phone numbers or street addresses. Those details stay on the official record, where the sponsor can change them.
- 28
- records post a phone or email for at least one California site
- 6
- post only an overall-study phone or email
- 6
- post no phone or email
Use the registry desk
Start with the question—not the drug’s reputation.
Every “official record” link opens ClinicalTrials.gov. These filters narrow records to read. They do not screen your diagnosis, medicines, health history, exclusions or the local site’s actual capacity.
40 records shown
Every filter stays in this browser tab. Nothing is sent or saved, and this page loads no analytics. A matching age range or posted contact is not a finding that you qualify. Region and city choices hide other listed locations; each visible location keeps its own posted status—or says when none was posted.
Registry says recruitingPsilocybin / ketamine
NCT05403086 official record ↗Treatment study
Pragmatic Trial of Psilocybin Therapy in Palliative Care
- Question
- Demoralization in palliative care
- Stage
- Phase 2
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2025-11
- Update posted
- Nov 25, 2025
The study compares psilocybin and ketamine. It is not a general depression trial.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
4 of 4 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗GreenbraeMarin Cancer CareRegistry says recruiting
San FranciscoUniversity of San FranciscoRegistry says recruiting
Los AngelesUniversity of California, Los AngelesRegistry says recruiting
TorranceLundquist Institute at Harbor-UCLA Medical CenterRegistry says recruiting
Registry says recruitingPsilocybin
NCT06233344 official record ↗Treatment-model study
Mindfulness-Assisted Psychedelic Therapy
- Question
- Mental health
- Stage
- Phase 2
- Posted age range
- 25+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 6, 2026
Read the eligibility section closely; the registry condition label is broad.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗Los AngelesUSC Brain and Creativity InstituteRegistry says recruiting
Registry says recruitingPsilocybin
NCT06399263 official record ↗Treatment study
Study of Psilocybin for Anorexia in Young Adults
- Question
- Anorexia nervosa
- Stage
- Phase 2
- Posted age range
- 18–25 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-01
- Update posted
- Mar 3, 2026
The registry shows two UCSF entries with different local statuses; verify the recruiting location in the federal record.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 2 listed California site posts a phone or email in the federal record.
Several locations, different contact fields. Contact placement differs across this record: only 1 of 2 listed California locations posts a phone or email. Do not assume the contact belongs to a recruiting location; match the city, facility and local status on the official record.
Open the official record for current details ↗San FranciscoUniversity of California, San FranciscoRegistry says recruiting
San FranciscoUniversity of California, San FranciscoNot yet recruiting
Registry says recruitingPsilocybin
NCT06455293 official record ↗Treatment study
Psilocybin Therapy for Depression in Parkinson's Disease
- Question
- Parkinson disease and depression
- Stage
- Phase 2
- Posted age range
- 40–80 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-05
- Update posted
- Aug 7, 2026
This is for a defined neurological and depression population, not depression generally.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗San FranciscoUniversity of California, San FranciscoRegistry says recruiting
Registry says recruitingCYB003 (psilocin analog)
NCT06793397 official record ↗Treatment study
A Study of a Deuterated Psilocin Analog in Major Depressive Disorder
- Question
- Major depressive disorder
- Stage
- Phase 3
- Posted age range
- 18–85 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-09
- Update posted
- Sep 25, 2026
CYB003 is investigational. Withdrawn California locations are deliberately omitted here.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
7 of 7 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗GlendaleBehavioral Research SpecialistsRegistry says recruiting
Los AngelesCalNeuro Research GroupRegistry says recruiting
Los AngelesLipov Medical GroupNot yet recruiting
OrangeATP Clinical ResearchRegistry says recruiting
OrangeNRC Research InstituteRegistry says recruiting
San Juan CapistranoInland Psychiatric Medical Group ResearchNot yet recruiting
Santa MonicaPsychedelic Science InstituteRegistry says recruiting
Registry says recruitingPsilocybin
NCT06814522 official record ↗Treatment-model study
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout
- Question
- Physician burnout
- Stage
- Phase 1 / Phase 2
- Posted age range
- 21–70 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2025-11
- Update posted
- Jul 21, 2026
Eligibility is limited to the population described in the study record.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗San DiegoUniversity of California, San DiegoRegistry says recruiting
Registry says recruitingPsilocybin
NCT07281352 official record ↗Treatment study
Psilocybin-Assisted CBT for Depression
- Question
- Major depressive disorder
- Stage
- Phase 1 / Phase 2
- Posted age range
- 21–60 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2025-12
- Update posted
- Feb 12, 2026
The study compares cognitive behavioral therapy and minimal supportive therapy around psilocybin.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗Los AngelesUCLA Semel InstituteRegistry says recruiting
Not yet recruitingPsilocybin
NCT07479550 official record ↗Treatment and mechanism study
Study of Psilocybin Under Anesthesia Controlled by EEG
- Question
- Major depression
- Stage
- Phase 2
- Posted age range
- 25–65 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-04
- Update posted
- May 6, 2026
The registry says not yet recruiting. Do not treat a listed contact as an enrollment promise.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗StanfordStanford UniversityLocation listed; no separate local status posted
Not yet recruitingPsilocybin
NCT07566104 official record ↗Treatment study
Group Psilocybin-Assisted CBT for Depression
- Question
- Major depressive disorder
- Stage
- Phase 2
- Posted age range
- 21–60 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-04
- Update posted
- May 4, 2026
The federal record does not yet list a central contact.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗Los AngelesUCLA Semel InstituteLocation listed; no separate local status posted
Not yet recruitingPsilocybin
NCT07756736 official record ↗Treatment study
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
- Question
- Methamphetamine use disorder and HIV
- Stage
- Phase 2
- Posted age range
- 25–64 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 11, 2026
This study is for people who meet both the substance-use and HIV eligibility criteria.
Official contact route · checked Oct 2, 2026
Overall study contact only
The federal record posts an overall study phone or email, but no listed California site posts a direct phone or email.
Open the official record for current details ↗San FranciscoUCSF at Zuckerberg San Francisco General HospitalLocation listed; no separate local status posted
Registry says recruitingLSD / lysergide (DT120, formerly MM120)
NCT07592689 official record ↗Treatment study
A Phase 3 Trial of DT120 for Major Depressive Disorder
- Question
- Major depressive disorder
- Stage
- Phase 3
- Posted age range
- 18–74 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-07
- Update posted
- Aug 10, 2026
The study drug is investigational lysergide tartrate. California sites have different statuses.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
4 of 4 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗San DiegoKadima Neuropsychiatry InstituteRegistry says recruiting
Santa MonicaPsychedelic Science InstituteRegistry says recruiting
OrangeATP Clinical Research Orange CountyNot yet recruiting
San FranciscoUCSF Department of NeurologyNot yet recruiting
Registry says recruitingMDMA
NCT05770375 official record ↗Safety and tolerability study
Tolerability of MDMA in Schizophrenia
- Question
- Schizophrenia
- Stage
- Phase 1 / Phase 2
- Posted age range
- 18–60 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-07
- Update posted
- Jul 17, 2026
This is an early safety and tolerability study, not approved schizophrenia treatment.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗Los AngelesUCLARegistry says recruiting
Registry says recruitingMDMA
NCT05783817 official record ↗Treatment study
MDMA-Assisted CBT for OCD
- Question
- Obsessive-compulsive disorder
- Stage
- Phase 2
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-03
- Update posted
- Mar 5, 2026
The protocol also includes methamphetamine as a comparator. Read the arms before volunteering.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗Palo AltoStanford University Medical CenterRegistry says recruiting
Registry says recruitingMDMA
NCT05790239 official record ↗Treatment study
MDMA-Assisted Therapy for Veterans With PTSD
- Question
- Moderate to severe PTSD in veterans
- Stage
- Phase 2
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 19, 2026
Veteran status and the full eligibility rules matter. Two Los Angeles VA entries have different local statuses.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 2 listed California site posts a phone or email in the federal record.
Several locations, different contact fields. Contact placement differs across this record: only 1 of 2 listed California locations posts a phone or email. Do not assume the contact belongs to a recruiting location; match the city, facility and local status on the official record.
Open the official record for current details ↗Los AngelesWest Los Angeles Veterans AffairsRegistry says recruiting
Los AngelesVA Greater Los Angeles, WestwoodNot yet recruiting
Registry says recruitingMDMA
NCT05837845 official record ↗Treatment study
MDMA-Assisted Cognitive Processing Therapy for Veterans With PTSD
- Question
- Severe PTSD in veterans
- Stage
- Phase 2
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2025-07
- Update posted
- Jul 31, 2025
The registry record is older than several others in this snapshot; verify it before acting.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗Palo AltoVA Palo Alto Health Care System / Stanford UniversityRegistry says recruiting
Registry says recruitingMethylone (TSND-201)
NCT07456696 official record ↗Treatment study
Safety and Efficacy of TSND-201 for PTSD
- Question
- Post-traumatic stress disorder
- Stage
- Phase 3
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-05
- Update posted
- Sep 17, 2026
Methylone is an investigational entactogen. It is not MDMA and is not approved PTSD care.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
7 of 7 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗ImperialSun Valley ResearchRegistry says recruiting
La JollaKadima NeuropsychiatryRegistry says recruiting
Los AngelesCalNeuro Research GroupRegistry says recruiting
MontclairCatalina Research InstituteRegistry says recruiting
OceansideExcell ResearchRegistry says recruiting
OrangeATP Clinical ResearchRegistry says recruiting
San Juan CapistranoInland Psychiatric Medical GroupRegistry says recruiting
Registry says recruitingKetamine
NCT05940324 official record ↗Treatment and mechanism study
Ketamine's Rapid Effects in OCD
- Question
- Obsessive-compulsive disorder
- Stage
- Phase 2
- Posted age range
- 18–65 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-04
- Update posted
- Apr 24, 2026
The trial examines a ketamine infusion with naltrexone or placebo; psychiatric use of FDA-approved ketamine injection is off-label.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗StanfordStanford Psychiatry and Behavioral SciencesRegistry says recruiting
Registry says recruitingHydroxynorketamine (RR-HNK)
NCT06575075 official record ↗Treatment and safety study
Pilot Study of RR-HNK in OCD
- Question
- Obsessive-compulsive disorder
- Stage
- Phase 1 / Phase 2
- Posted age range
- 18–65 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 12, 2026
RR-HNK is a ketamine metabolite under study. It is not an approved OCD medication.
Official contact route · checked Oct 2, 2026
Overall study contact only
The federal record posts an overall study phone or email, but no listed California site posts a direct phone or email.
Open the official record for current details ↗Palo AltoStanford University School of MedicineRegistry says recruiting
Not yet recruitingKetamine
NCT07369089 official record ↗Treatment study
Ketamine-Assisted Mindfulness-Oriented Recovery for Opioid Use Disorder
- Question
- Treatment-resistant opioid use disorder
- Stage
- Phase 2
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-01
- Update posted
- Feb 3, 2026
The registry says not yet recruiting. This does not replace established medications for opioid use disorder.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗La JollaUniversity of California, San DiegoLocation listed; no separate local status posted
Invitation onlyEsketamine
NCT07396220 official record ↗Care-model study
Psychotherapy With Intranasal Esketamine for Suicidal Ideation
- Question
- Suicidal ideation
- Stage
- Not applicable
- Posted age range
- 18–70 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-01
- Update posted
- Feb 9, 2026
Invitation-only means participants come from a predetermined population. It is not a public enrollment route or crisis service.
Official contact route · checked Oct 2, 2026
No phone or email posted
The federal record posts no phone or email for the overall study or its listed California sites. That does not prove the study is closed.
Open the official record for current details ↗San DiegoUC San Diego Health — 4S RanchLocation listed; no separate local status posted
Invitation onlyKetamine
NCT06034821 official record ↗Comparative treatment study
ECT Versus Ketamine Over the Lifespan
- Question
- Acute suicidal depression
- Stage
- Phase 4
- Posted age range
- 18–90 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2025-12
- Update posted
- Dec 15, 2025
Invitation-only is not a crisis access path. In immediate danger, use 988, 911, or the nearest emergency department.
Official contact route · checked Oct 2, 2026
No phone or email posted
The federal record posts no phone or email for the overall study or its listed California sites. That does not prove the study is closed.
Open the official record for current details ↗San FranciscoUniversity of California, San FranciscoLocation listed; no separate local status posted
Registry says recruitingEsketamine
NCT07716098 official record ↗Treatment study
Esketamine Nasal Spray Versus Placebo in Treatment-Resistant Depression
- Question
- Treatment-resistant depression
- Stage
- Phase 3
- Posted age range
- 18+ years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-09
- Update posted
- Sep 25, 2026
This is a specific research protocol. It does not describe every FDA-approved use of Spravato.
Official contact route · checked Oct 2, 2026
Overall study contact only
The federal record posts an overall study phone or email, but no listed California site posts a direct phone or email.
Open the official record for current details ↗RedlandsAnderson Clinical ResearchRegistry says recruiting
San DiegoArtemis Institute for Clinical ResearchRegistry says recruiting
Not yet recruitingDMT
NCT07693257 official record ↗Healthy-volunteer mechanism study
Neural Effects of Intravenous DMT
- Question
- Healthy participants
- Stage
- Phase 1
- Posted age range
- 18–65 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-07
- Update posted
- Jul 9, 2026
This study examines neural effects. It is not a mental-health treatment study.
Official contact route · checked Oct 2, 2026
Overall study contact only
The federal record posts an overall study phone or email, but no listed California site posts a direct phone or email.
Open the official record for current details ↗La JollaAltman Clinical and Translational Research InstituteLocation listed; no separate local status posted
Registry says recruitingIbogaine
NCT07226570 official record ↗Observational study
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
- Question
- Opioid use disorder
- Stage
- Not applicable
- Posted age range
- 21–70 years
- Purpose
- Observational study
- Sponsor verification month
- 2026-05
- Update posted
- May 18, 2026
The registered intervention is MRI/EEG observation. The California study does not provide ibogaine treatment.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗IrvineUC Irvine Susan Samueli Integrative Health InstituteRegistry says recruiting
Registry says recruitingPsilocybin
NCT05265546 official record ↗Healthy-volunteer mechanism study
Effects of Psilocybin on Visual Perception and Brain Representations
- Question
- Visual perception
- Stage
- Phase 1
- Posted age range
- 21+ years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-07
- Update posted
- Jul 10, 2026
This is not a treatment study.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗BerkeleyUniversity of California, BerkeleyRegistry says recruiting
Registry says recruitingPsilocybin
NCT06367738 official record ↗Healthy-volunteer mechanism study
Persisting Effects of Psilocybin on Structural Plasticity in Older Adults
- Question
- Healthy older adults
- Stage
- Phase 1
- Posted age range
- 60–85 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2025-10
- Update posted
- Oct 21, 2025
This is not treatment for a diagnosed condition.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗BerkeleyUniversity of California, BerkeleyRegistry says recruiting
Registry says recruitingPsilocybin
NCT06626139 official record ↗Mechanism and context study
Interaction of Psilocybin and the Context of Administration
- Question
- Healthy participants with lower-than-average well-being
- Stage
- Phase 2
- Posted age range
- 21–70 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-06
- Update posted
- Jun 4, 2026
The study tests context as part of the intervention. It is not ordinary psychotherapy access.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗San FranciscoUCSF Mission BayRegistry says recruiting
Invitation onlyPsilocybin
NCT06919640 official record ↗Mechanism study
Psilocybin With Intracranial Neural Sensing
- Question
- Chronic pain
- Stage
- Phase 1
- Posted age range
- 21–75 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2025-04
- Update posted
- Jun 6, 2025
Invitation-only means this is not a public enrollment or treatment route.
Official contact route · checked Oct 2, 2026
No phone or email posted
The federal record posts no phone or email for the overall study or its listed California sites. That does not prove the study is closed.
Open the official record for current details ↗San FranciscoUniversity of California, San FranciscoLocation listed; no separate local status posted
Registry says recruitingPsilocybin
NCT07386730 official record ↗Healthy-volunteer mechanism study
Psychedelics in Healthy Older Adults With Low Well-Being
- Question
- Older adults with low well-being
- Stage
- Phase 1
- Posted age range
- 50–85 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2025-12
- Update posted
- Jun 8, 2026
This is not depression treatment and should not be described that way.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗San FranciscoUCSF Sandler Neuroscience BuildingRegistry says recruiting
Registry says recruitingPsilocybin
NCT07516405 official record ↗Healthy-volunteer safety study
Safety and Tolerability of Psilocybin in Healthy Older Adults
- Question
- Healthy adults ages 65–85
- Stage
- Phase 1
- Posted age range
- 65–85 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 10, 2026
This is a safety and tolerability study, not a treatment trial.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗San FranciscoUCSF Department of NeurologyRegistry says recruiting
Registry says recruitingRE104
NCT07002034 official record ↗Treatment study
RE104 for Adjustment Disorder With Cancer or Other Medical Illness
- Question
- Adjustment disorder with cancer or another medical illness
- Stage
- Phase 2
- Posted age range
- 18–80 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 24, 2026
RE104 is investigational. This record is limited to the diagnosis and medical-illness criteria in the protocol.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
2 of 2 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗San DiegoKadima Neuropsychiatry InstituteRegistry says recruiting
Santa RosaProvidence Medical FoundationRegistry says recruiting
Registry says recruitingRE104
NCT07489651 official record ↗Treatment study
RE104 for Generalized Anxiety Disorder
- Question
- Generalized anxiety disorder
- Stage
- Phase 2
- Posted age range
- 18–74 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-05
- Update posted
- Aug 18, 2026
RE104 is investigational. A recruiting site and a study result are not an approved anxiety treatment.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
4 of 4 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗Garden GroveCollaborative Neuroscience ResearchRegistry says recruiting
La JollaKadima Neuropsychiatry InstituteRegistry says recruiting
San FranciscoOpen Mind TherapeuticsRegistry says recruiting
Santa MonicaTRIP Clinic at Psychedelic Science InstituteRegistry says recruiting
Invitation onlyKetamine
NCT06736769 official record ↗Treatment and mechanism study
Ketamine Effects on Learning in Eating Disorders
- Question
- Anorexia nervosa or atypical anorexia nervosa
- Stage
- Phase 2
- Posted age range
- 16–26 years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2025-06
- Update posted
- Jun 12, 2026
The posted age range begins at 16, but enrollment is invitation-only. This is not an adolescent care or referral route.
Official contact route · checked Oct 2, 2026
No phone or email posted
The federal record posts no phone or email for the overall study or its listed California sites. That does not prove the study is closed.
Open the official record for current details ↗San FranciscoUniversity of California, San FranciscoLocation listed; no separate local status posted
Registry says recruitingKetamine
NCT05962424 official record ↗Safety and mechanism study
Human Neural Circuits Electrophysiology During Cognition
- Question
- Neural circuits in people receiving psychiatric care
- Stage
- Phase 1
- Posted age range
- 18+ years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-04
- Update posted
- Apr 22, 2026
The record studies brain signals during cognition. It is not ordinary ketamine treatment or proof that ketamine treats every listed psychiatric condition.
Official contact route · checked Oct 2, 2026
Overall study contact only
The federal record posts an overall study phone or email, but no listed California site posts a direct phone or email.
Open the official record for current details ↗Palo AltoStanford UniversityRegistry says recruiting
Registry says recruitingKetamine
NCT04861051 official record ↗Safety and mechanism study
Understanding Ketamine's Dissociative Effects
- Question
- Ketamine dissociation in people with epilepsy
- Stage
- Phase 1
- Posted age range
- 18+ years
- Purpose
- Safety or mechanism study
- Sponsor verification month
- 2026-04
- Update posted
- Apr 22, 2026
This study examines dissociation in a defined epilepsy population. It is not a depression-treatment trial.
Official contact route · checked Oct 2, 2026
Overall study contact only
The federal record posts an overall study phone or email, but no listed California site posts a direct phone or email.
Open the official record for current details ↗Palo AltoStanford University School of MedicineRegistry says recruiting
Invitation onlyCYB003 (psilocin analog)
NCT06605105 official record ↗Extension treatment study
CYB003 Long-Term Extension Study in Major Depressive Disorder
- Question
- Major depressive disorder
- Stage
- Phase 3
- Posted age range
- 18–85 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-09
- Update posted
- Sep 25, 2026
This is an extension study for a predetermined participant population, not open enrollment for CYB003 treatment.
Official contact route · checked Oct 2, 2026
No phone or email posted
The federal record posts no phone or email for the overall study or its listed California sites. That does not prove the study is closed.
Open the official record for current details ↗GlendaleBehavioral Research SpecialistsLocation listed; no separate local status posted
La JollaKadima Neuropsychiatry InstituteLocation listed; no separate local status posted
Los AngelesCalNeuro Research GroupLocation listed; no separate local status posted
Los AngelesLipov Medical GroupLocation listed; no separate local status posted
Los AngelesTRIP Clinic and Psychedelic Science InstituteLocation listed; no separate local status posted
OceansideExcell ResearchLocation listed; no separate local status posted
San FranciscoOpen Mind Collective / UCSF Medical Center — Mount ZionLocation listed; no separate local status posted
San Juan CapistranoInland Psychiatric Medical Group ResearchLocation listed; no separate local status posted
Registry says recruitingEsketamine
NCT07528014 official record ↗Observational study
Longitudinal Assessment of Depression Treatment Response
- Question
- Depressed mood during standard-care esketamine or TMS
- Stage
- Not applicable
- Posted age range
- 18+ years
- Purpose
- Observational study
- Sponsor verification month
- 2026-04
- Update posted
- Apr 14, 2026
The study observes people already prescribed standard-care esketamine, TMS or SAINT. The research record does not assign or provide that treatment.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
2 of 2 listed California sites post a phone or email in the federal record.
Open the official record for current details ↗La JollaSalma HealthRegistry says recruiting
Laguna HillsSalma HealthRegistry says recruiting
Invitation onlyEsketamine
NCT06823024 official record ↗Observational study
Speech Markers of Response to Spravato or TMS
- Question
- Depression, PTSD or bipolar disorder during standard care
- Stage
- Not applicable
- Posted age range
- 18–68 years
- Purpose
- Observational study
- Sponsor verification month
- 2025-02
- Update posted
- Mar 18, 2025
The study records speech from people already scheduled for Spravato or TMS. It does not assign the treatment, and invitation-only is not a public access route.
Official contact route · checked Oct 2, 2026
No phone or email posted
The federal record posts no phone or email for the overall study or its listed California sites. That does not prove the study is closed.
Open the official record for current details ↗SunnyvaleAcacia ClinicsLocation listed; no separate local status posted
Registry says recruitingKetamine / esketamine
NCT06526078 official record ↗Care-model study
Cognitive Training as an Adjunct to Ketamine in Real-World Clinics
- Question
- Depressive disorders during existing ketamine or esketamine care
- Stage
- Not applicable
- Posted age range
- 18–80 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-08
- Update posted
- Aug 19, 2026
The research intervention is cognitive training. Participants must already be clinically enrolled for ketamine or esketamine care; the Oakland site itself says not yet recruiting.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗OaklandKaiser Foundation Research InstituteNot yet recruiting
Registry says recruitingKetamine
NCT06231563 official record ↗Treatment and mechanism study
Ketamine for Depression in Veterans With Parkinson's Disease
- Question
- Depression in veterans with Parkinson's disease
- Stage
- Phase 2
- Posted age range
- 40–80 years
- Purpose
- Treatment or care-model study
- Sponsor verification month
- 2026-04
- Update posted
- Apr 13, 2026
The official title names depression, neuroplasticity and inflammation in veterans with Parkinson's disease. It is not a general Parkinson's or depression-care route.
Official contact route · checked Oct 2, 2026
At least one California site contact posted
1 of 1 listed California site posts a phone or email in the federal record.
Open the official record for current details ↗San FranciscoSan Francisco VA Medical CenterRegistry says recruiting
No record matches those filters.
Change one filter, or use the federal registry for a broader search. An empty result here does not prove that no study exists.
The only record here with a posted range below 18 begins at age 16 and enrolls by invitation. It is not a public referral route or a care plan for a child or teenager.
Status hold · not an enrollment route
Three records have no verified current status.
ClinicalTrials.gov shows “Unknown” when a formerly recruiting, coming, or active-not-recruiting record has passed its completion date and the responsible party has not verified the status within two years. The registry treats it as closed. Unknown does not tell us whether the study completed, stopped, or remains active.
Read the federal definition of Unknown ↗Developing anesthesia as PTSD therapy
ClinicalTrials.gov now labels this record Unknown and treats it as closed. This Phase 1 basic-science study tested low doses of several anesthetic drugs in healthy adults during emotional-memory and brain-imaging tasks. Ketamine was one of several drugs. It did not provide PTSD treatment, and Unknown does not establish whether the study completed, stopped, or remains active.
Healthy-volunteer mechanism study. Question: Emotional-memory mechanisms relevant to future PTSD research. Posted age range: 18–35 years. Last known status: Active; not recruiting. Sponsor last verified it in October 2016; its last update was posted Oct 13, 2016. Estimated completion date: April 2017. California city named: Irvine. Status checked here Oct 2, 2026.
Source conflict. The title says PTSD therapy, while the registry condition is Healthy, the purpose is basic science, and the eligibility text excludes people with mental illness. The placebo arm also lists all five intervention names.
NCT01736020 official record ↗Micro-dose ketamine record for frontline healthcare workers
ClinicalTrials.gov now labels this record Unknown and treats it as closed. It describes a retrospective chart review of a past open-label sublingual ketamine program for frontline healthcare workers with acute stress disorder. It does not establish that the program is operating or accepting anyone, and Unknown does not establish whether the study completed, stopped, or remains active.
Retrospective treatment record. Question: Acute stress disorder. Posted age range: 18+ years. Last known status: Active; not recruiting. Sponsor last verified it in February 2021; its last update was posted Feb 24, 2021. Estimated completion date: April 2021. California city named: Toluca Lake. Status checked here Oct 2, 2026.
Source conflict. The registry labels the record Phase 4, interventional and treatment, but its own summary and design description call it a retrospective chart review. It also marks healthy volunteers eligible while requiring acute-stress-disorder screening. Phase 4 does not establish FDA approval of this formulation or use.
NCT04769297 official record ↗Psilocybin in treatment-resistant depression
ClinicalTrials.gov now labels this record Unknown because the responsible party has not verified its last known active-not-recruiting status within two years and the estimated study completion date has passed. The registry treats Unknown records as closed. This does not establish whether the study completed, stopped, or remains active.
Treatment study. Question: Treatment-resistant depression. Posted age range: 18–65 years. Last known status: Active; not recruiting. Sponsor last verified it in August 2024; its last update was posted Aug 9, 2024. Estimated completion date: May 1, 2026. California city named: Palo Alto. Status checked here Oct 2, 2026.
NCT04433858 official record ↗Evidence only · not an enrollment route
One record is suspended.
Safety profile of psilocybin for cocaine use disorder
The registry says suspended. This is not a current enrollment route; read the federal record for the sponsor-posted reason and any later update.
NCT06102434 official record ↗Follow the evidence; do not ask for a place
Active studies that are not recruiting.
These records may still produce results. “Active, not recruiting” means participants are still receiving an intervention or being examined, but new participants are not currently being enrolled.
LSD / lysergide · Phase 3
DT120 for generalized anxiety disorder (Voyage)
Generalized anxiety disorder · La Jolla, San Francisco, Santa Monica
NCT06741228 official record ↗LSD / lysergide · Phase 3MM120 for generalized anxiety disorder (Panorama)
Generalized anxiety disorder · Los Angeles
NCT06809595 official record ↗LSD / lysergide · Phase 3DT120 for major depressive disorder (Emerge)
Major depressive disorder · La Jolla, Santa Monica
NCT06941844 official record ↗MDMA · Phase 3MDMA-assisted massed prolonged exposure for PTSD
Post-traumatic stress disorder · San Diego
NCT06117306 official record ↗Ibogaine · ObservationalIbogaine-magnesium in veterans with repeated blast exposure
Blast or combat exposure and head injury · Stanford
NCT04313712 official record ↗Ibogaine + 5-MeO-DMT · ObservationalTrifecta Research Study
PTSD, brain injury, depression and suicidal ideation · Northridge
NCT07717866 official record ↗Psilocybin · Phase 3Psilocybin for major depressive disorder
Major depressive disorder · La Jolla, Los Angeles, Santa Monica
NCT06308653 official record ↗Psilocybin · Phase 1 / Phase 2Psilocybin therapy for chronic low back pain
Chronic low-back pain · San Francisco
NCT05351541 official record ↗Ketamine · Phase 2Ketamine for methamphetamine use disorder
Methamphetamine use disorder · San Leandro
NCT06496750 official record ↗Psilocybin · Phase 2COMP360 in recurrent major depressive disorder
Recurrent major depressive disorder · La Jolla
NCT05733546 official record ↗Psilocybin · Phase 2Set and setting in psilocybin-assisted therapy for alcohol use disorder
Alcohol use disorder · Santa Monica
NCT04410913 official record ↗Psilocin / psilocybin · Phase 1Comparing psilocin and psilocybin in healthy adults
Healthy participants · San Francisco
NCT05317689 official record ↗Psilocybin · Phase 1Neural and physiological correlates of psychedelic sub-states
Healthy participants · San Francisco
NCT05698511 official record ↗Ketamine · Phase 4Ketamine during sedation for chronic pain and depression
Chronic pain and depression · Stanford
NCT06317636 official record ↗Psilocybin · Phase 2Psilocybin therapy for depression in bipolar II disorder
Bipolar II depression · San Francisco
NCT05065294 official record ↗CYB003 (psilocin analog) · Phase 3CYB003 in major depressive disorder
Major depressive disorder · Bellflower, La Jolla, Los Angeles, Montclair, Oceanside, San Francisco, San Juan Capistrano
NCT06564818 official record ↗Psilocybin (COMP360) · Phase 3Two administrations of COMP360 in treatment-resistant depression
Treatment-resistant depression · Bellflower, Encino, La Jolla, Los Angeles, Montclair, Oakland, Orange, Riverside, San Jose, Santa Ana, Stanford, Thousand Oaks, Upland
NCT05711940 official record ↗An honest zero
No California treatment route appeared in this snapshot.
Ayahuasca
No recruiting or not-yet-recruiting California treatment study appeared in the intervention search used for this snapshot.
Mescaline
No recruiting or not-yet-recruiting California treatment study appeared in the intervention search used for this snapshot.
5-MeO-DMT
One California observational combination record was active but not recruiting; no recruiting California treatment study appeared in this snapshot.
This is a result of a dated registry search, not proof that research does not exist elsewhere or that the result will remain zero. Ayahuasca, mescaline and 5-MeO-DMT are not FDA-approved mental-health treatments, and this dated official-source review identified no statewide California licensed-treatment system for them.
When a contact is posted
Carry the study number. Keep your private history private.
The first message only needs to identify the study and the California location. Confirm that you have reached the study team before sending diagnoses, medication lists, records, insurance information or identity documents.
“I’m asking about NCT________ and the ________ site. Is that location currently screening new participants? If it is, what is the secure first step?”
- Ask about the local site.The overall study can say recruiting while one California location is not.
- Ask how screening works.A posted age range or diagnosis does not settle the full eligibility rules.
- Ask before sending records.Use the study team’s secure route, not an address copied into another website.
- Never pay a broker for access.The official record is the route. A third-party “trial waitlist” is not enrollment.
Before you volunteer
Ask the questions the headline leaves out.
- Which part of the eligibility rules fits me?A diagnosis alone rarely qualifies someone.
- Is the California site itself recruiting?The overall study and the local site can have different statuses.
- What could I receive?Ask about placebo, comparator, dose, randomization and masking.
- What must I stop or change first?Do not change medication from a webpage; ask the study and your own prescriber.
- How many visits and how much travel?Screening, dosing and follow-up may happen on different days.
- What costs, payment or compensation apply?A study can cover research procedures without covering ordinary medical care.
- Who handles a medical or psychiatric emergency?Get the onsite and after-hours plan before consent.
- Who pays if research causes an injury?Read the consent form; do not accept a verbal summary.
If you need care rather than research
Do not wait for a study to become treatment.
Depression, PTSD, OCD and substance-use disorders already have established care routes. A trial can be a research choice for someone who qualifies; it is not the price of receiving help now.
The registry record is the source of status—not the study advertisement.
- ClinicalTrials.gov, API v2 and each linked NCT study record. Registry status, posted-update and eligibility fields for 40 open, coming or invitation-only records, 17 active records closed to enrollment, 3 status-unknown records, and 1 suspended record were rechecked August 31, 2026. The complete set was last read in full August 28; the three Unknown records and the two new discovery-ledger decisions were read August 31.
- ClinicalTrials.gov, protocol registration definitions and Unknown status definition: recruiting, not yet recruiting, enrolling by invitation, active not recruiting, suspended, and the stale-status boundary.
- ClinicalTrials.gov, How to Read a Study Record and Study Data Structure: sponsor-entered status, central and location contact fields, locations, eligibility and update dates. Contact-route presence was checked August 30, 2026; contact names and details are not republished here.
- U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, final guidance, July 2026.
- U.S. Food and Drug Administration, Development and Approval Process: research stages and what FDA approval means.
- U.S. Food and Drug Administration, access to investigational drugs: clinical trials and expanded-access routes are distinct.
- Drug Enforcement Administration, Hallucinogens Drug Fact Sheet, 2024 edition: federal controlled-substance status and risks.
- Governor of California, SB 58 veto message, October 7, 2023: the statewide decriminalization proposal did not become law.
Educational information, not medical advice, legal advice, research recruitment, a recommendation to enroll, or a claim that a study will accept you. Registry status and posted eligibility ranges checked August 31, 2026; presence of a phone or email checked August 30, 2026. A weekly automated watch checks every curated record and unions two high-recall ClinicalTrials.gov searches; new or changed records open an editorial review item and never publish themselves. Next full human review is due November 26, 2026. Licensed-prescriber and California legal review pending. Paid for by participating therapists. Inclusion is computed, never purchased. No ads. No data sold.